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ABSTRACT
Introduction: Diabetes mellitus (DM) is present
in 10–15% of the surgical population. It is a
known risk factor for adverse postoperative
outcomes. UK perioperative guidance recom-
mends optimizing glycemic control preopera-
tively, aiming for a target glycated hemoglobin
(HbA1c) of\69 mmol/mol. However, real-
world compliance with this guidance remains
unknown. The aim of our study was to deter-
mine how many patients with DM undergoing
elective orthopedic and vascular surgery had a
preoperative HbA1c of\ 69 mmol/mol. We also
reviewed the surgical reasons for non-
concordance with the recommended preopera-
tive HbA1c target.
Methods: This was a retrospective observa-
tional study of 1000 consecutive patients who
had been referred for elective vascular and
orthopedic surgery at a large tertiary center.
Data were collected on these patients, both
those with and without DM, between January
2016 and February 2017. Electronic databases
were used to collect information on the
patients’ preoperative HbA1c concentration and
to determine whether there was a resulting
delay in surgery when the preoperative HbA1c
target of\ 69 mmol/mol was exceeded.
Results: Of the 1000 patients referred for surgery
(500 orthopedic and 500 vascular patients)
included in the study, 201 (20%) had diabetes.
Among these 201 people with DM, 155 (77%) had
a preoperative HbA1c\69 mmol/mol. Among
the 46 people with DM whose HbA1c exceeded
the recommended target, 41 were operated on
despite the high HbA1c level, and only five had
their surgery deferred or canceled due to subop-
timal preoperative glycemic control.
Conclusions: Our data shows that the majority
(77% ) of people undergoing elective vascular
and orthopedic surgery were able to achieve a
target HbA1c of \ 69 mmol/mol. The current
preoperative guidance is therefore achievable in
a real-life setting. However, as is stated in the
national guidance, this target should only be
used where it is safe to do so and a degree of
clinical discretion is necessary.
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INTRODUCTION
The prevalence of diabetes mellitus (DM) is
increasing in the UK, where it has been esti-
mated that there are currently 3.8 million
adults with DM, equivalent to 8.6% of the
adult population [1]. This is an increase from
the estimate of 2.7 million (6% of the adult
population) in 2013 [2]. Recent studies have
shown that 8.8% of surgical referrals to all
specialities are for persons with diabetes, and
that 10–15% of those who ultimately undergo
surgery have DM [3, 4]. This figure is expected
to increase alongside increases in the preva-
lence of DM.
Poor perioperative diabetes control has been
shown to be associated with adverse outcomes
in almost every surgical speciality [5–18],
although it is acknowledged that these data
show an association and not causation. How-
ever, given the strength of the association,
national guidelines recommend that glycemic
control be optimized prior to elective surgery—
i.e. the patient should achieve a glycated
hemoglobin (HbA1c) of B 69 mmol/mol (8.5%),
where it is safe to do so [4, 19]. To date there are
few data on how closely clinicians adhere to this
standard at the preoperative assessment, or
whether this target is achievable.
The aim of this single-center study was to
determine how many orthopedic and vascular
surgery patients with DM in a convenience
sample had a preoperative HbA1c above the
recommended target of 69 mmol/mol (8.5%),
and how many ultimately underwent surgery
despite having an HbA1c which exceeded the
target.
METHODS
We carried out a retrospective review of a con-
venience sample of 1000 consecutive vascular
and orthopedic patients who had a preoperative
assessment between 15 January 2016 and 20
February 2017 at the Norfolk and Norwich
University Hospital (NNUH), a 1000-bed teach-
ing hospital in the East of England.
All patients who require an elective vascular
or orthopedic procedure are seen in a preoper-
ative assessment clinic in the 2 weeks preceding
their surgery. This clinic is run by experienced
nursing staff with anaesthetic medical support.
For those with significant co-morbidities, the
assessments are undertaken by the anaesthetists
themselves.
Patients attending their assessment were
identified using the hospital’s patient adminis-
tration system (PAS). Details of patients’ pre-
operative assessment were found using internal
electronic databases (Orsos Web Periop [All-
scripts, Manchester UK] and Bluespier [Droit-
wich, UK]). Sunquest ICE (Integrated Clinical
Environment, an online pathology requesting
and reporting system [Tucson, AZ]) and online
outpatient clinic letters were then used to col-
lect data on the patients’ HbA1c and any
resulting delay in their elective surgery. Patients
with and without DM were included in the
study.
The study was registered as a local clinical
audit (registration code DIAB-17-18-08) and as
such ethical approval was not required. The
study was registered with Researchregistry.com,
registration number 4756. Reporting of this
work followed the STROCSS (Strengthening the
Reporting of Cohort Studies in Surgery) criteria.
[20].
RESULTS
Demographics and Type of Surgery
Of the 1000 consecutive patients reviewed, the
median age was 69 (range 16–92) years, 42%
were female and 20% had diabetes (Table 1).
There was an even split between vascular and
orthopedic surgery patients. The type of surgery
performed is summarized in Table 2.
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HbA1c Concentration
Overall there were 201 patients with DM,
among whom 155 (77%) achieved an HbA1c
below the target of 69 mmol/mol (8.5%) prior
to their surgery. A total of 46 patients (23%)
with DM did not meet the recommended pre-
operative HbA1c target.
Of the 46 individuals with DM who had a
preoperative HbA1c C 69 mmol/mol (8.5%), 41
underwent surgery irrespective of their preop-
erative glycemic control. The procedures car-
ried out for these individuals are listed in
Table 3. The remaining five individuals had
their surgery deferred or canceled as a result of
suboptimal preoperative glycemic control.
Deferred Surgeries
The details of the five individuals who had their
surgery delayed or canceled due to a high HbA1c
concentration are summarized in Table 4.
The surgery of one individual who was
scheduled to have a vascular procedure for an
occluded superior femoral artery stent, for
which a femoro-distal bypass was indicated, was
canceled due to high HbA1c. However, because
the patient had continued poor glycemic con-
trol but the symptoms showed an improve-
ment, surgery was no longer deemed urgent,
and the decision was made to continue con-
servative treatment. This individual had the
highest HbA1c readings of all the patients
included in this study (134 and 140 mmol/mol
[14.4 and 15%, respectively]).
Of the seven orthopedic patients with an
HbA1c of C 69 mmol/mol, only three ultimately
had their respective surgery without delay. The
HbA1c values of these three patients were 74, 72,
and 69 mmol/mol (8.9, 8.7 and 8.5%), respec-
tively. The patient with the HbA1c of
74 mmol/mol (8.9%) underwent an urgent foot
amputation following a diagnosis of
osteomyelitis.
No further preoperative assessments or
admission details were found for the two
patients with high HbA1c concentrations
awaiting total hip replacements. These patients
may have had their surgery elsewhere or had
their surgery canceled altogether, thereby opt-
ing for conservative management.
Table 1 Glycemic status and type of diabetes for all 1000 patients in the study
Type of diabetes Frequency (n) Percentage (%) Gender (male:female) Age (– SD)
No diabetes 796 79.6 344:452 64.3 (16.3)
Type 1 10 1.0 5:5 59.7 (14.8)
Type 2 181 18.1 64:117 69.7 (10.5)
Type unknown 10 1.0 4:6 69.2 (7.4)
Borderlinea 2 0.2 2:0 82.0 (0.0)
Prediabetesa 1 0.1 0:1 76.0 (0.0)
Total 1000 100.0 418:582 65.4 (15.5)
SD Standard deviation
a Those recorded as ‘borderline’ or ‘prediabetes’ had a glycated hemoglobin (HbA1c) concentration of between 43 and
47 mmol/mol, a fasting glucose concentration of 6.0–6.9 mmol/l or a random plasma glucose level of 7.8–11.0 mmol/l
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Table 2 Type of surgery performed
Type of surgery Frequency
(n)
Percentage
(%)
Amputation 14 1.3
Aneurysm repair 4 0.4
Angiography 8 0.8
Angioplasty 86 8.6
Ankle surgery 11 1.1
Anterior cruciate ligament
repair
13 1.3
Aortic aneurysm open repair 47 4.7
Arthroscopy 34 3.4
Aspiration 1 0.1
Biopsy 1 0.1
Bypass 21 2.1
Elbow replacement 1 0.1
Endarterectomy 45 4.5
Endovascular aneurysm repair 73 7.3
Excision clavicle 1 0.1
Femoro-popliteal bypass 17 1.7
Fenestrated endovascular
aneurysm repair
11 1.1
Aorto-venous ﬁstula 71 7.1
Foot surgery 13 1.3
Hand surgery 9 0.9
Hardware removal 18 1.8
Hip replacement 130 13.0
Iliac stent 16 1.6
Knee replacement 121 12.1
Manipulation under
anaesthesia
3 0.3
Other 35 3.5
Profundoplasty 2 0.2
Rotator cuff repair 3 0.3
Scan under general
anaesthetic
3 0.3
Table 2 continued
Type of surgery Frequency
(n)
Percentage
(%)
Shoulder replacement 19 1.9
Soft tissue removal 8 0.8
Spinal procedure 76 7.6
Thoracic endovascular
aneurysm repair
1 0.1
Unknown 3 0.3
Varicose veins 73 7.3
Wrist surgery 3 0.3
Total 1000 100
Table 3 Type of surgery performed without deferment on
those with glycated hemoglobim concentrations that
exceeded 69 mmol/mol
Type of surgery Frequency
(n)
Percentage
(%)
Amputation 3 7.3
Angiogram 2 4.9
Angioplasty 15 36.6
Endarterectomy 7 17.1
Endovascular aneurysm
repair
2 4.9
Femoro-popliteal bypass 1 2.4
Fistula 3 7.3
Hip replacement 1 2.4
Iliac stent 2 4.9
Open aortic aneurysm
repair
2 4.9
Spinal procedure 1 2.4
Varicose veins 2 4.9
Total 41 100.0
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DISCUSSION
Our study shows that of 201 vascular and
orthopedic patients with DM, only 46 (23%)
had a pre-operative HbA1c C 69 mmol/mol
(8.5%). Of these latter 46 patients, only five
individuals had their surgery deferred or can-
celed due to exceeding the target HbA1c con-
centration, while the majority (41/46)
underwent surgery as planned.
Our institution is a 1000-bed tertiary teach-
ing hospital that primarily serves the popula-
tion of Norfolk, UK as well as neighboring
counties. The prevalence of DM (diagnosed and
undiagnosed) in Norfolk alone was estimated at
68,098 in 2015 [1]. At the time of the 2017
National Diabetes Inpatient Audit there were
140 inpatients with DM at the NNUH,
accounting for 15.9% of the total number of
beds included in the audit [21].
It is clear that if poor glycemic control was
not picked up by the diabetes caregiver prior to
the patient attending the the preoperative
assessment clinic, then 2 weeks would be
insufficient time to optimize glycemic control
and the decision on whether to defer surgery
would depend on the outcome of a discussion
between the anaesthetist and the surgeon. The
predominant factor in this discussion would be
the urgency of the surgery. In line with UK
national guidelines, the preoperative assess-
ment clinic staff does not manage the diabetes
care of individuals other than giving out
instructions on how to manage their diabetes
medications on the day prior to and on the day
of surgery [19]. Among the patients reviewed
here, those whose surgery could be safely
deferred were asked to return to their primary
diabetes caregiver who would then apply the
current standard of care to improve glycemic
control. These patients were sent to their dia-
betes caregiver with the information that the
delay in surgery was due to poor glycemic con-
trol, and they were given additional informa-
tion on the glycemic target. The vast majority of
patients with type 1 diabetes ([98%) in our
study were looked after by secondary care ser-
vices, while[80% of those with type 2 diabetes
were looked after by primary care services.
We believe that the sample size was large
enough to allow for the primary analysis—i.e. to
determine how many patients with DM had a
pre-operative HbA1c below the target of
69 mmol/mol (8.5%) for elective orthopedic
and vascular surgery. We were also able to
review any patients who had a delay in their
surgery due to high HbA1c. A strength of our
study is that it was a single-center study which
enabled us to comprehensively collect the data
Table 4 Details of patients whose surgery was delayed/canceled due to high glycated hemoglobin concentration
Specialty Procedure Age
(years)
Gender Type of
diabetes
mellitus
Pre-clinic HbA1c
(mmol/mol)
Repeat HbA1c
(mmol/mol)
Surgical
outcome
Vascular Femoro-popliteal
bypass
47 Female 2 134 140 Cancelled
Orthopedics Removal of
hardware from
femur
73 Female 2 79 59 Delayed
Orthopedics Wrist fusion 55 Male 1 84 63 Delayed
Orthopedics Total hip
replacement
65 Male 2 87 – Cancelled
Orthopedics Total knee
replacement
70 Male 2 81 71 Cancelled
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on HbA1c and on whether surgery went ahead
or not.
A limitation in our data was that we did not
collect information on interventions imple-
mented to optimize glycemic control before the
preoperative assessment, a task which may have
been performed by primary or secondary care
teams [4, 19]. Such data would have demon-
strated whether patients with high HbA1c con-
centrations were being targeted for
optimization of glycemic control before being
referred for surgery. In addition, the aim of this
study was not to look at any excess morbidity
and mortality following surgery in patients with
an HbA1c C 69 mmol/mol. We are aware that
the sample size was too small for such a study,
and other work is ongoing to address this
question. Further limitations to our study
include not collecting data on the use of con-
tinuous glucose monitoring or insulin pump
use nor on who was at high risk of developing
hypoglycemia.
Data are available which show that post-op-
erative outcomes worsen with worsening of
preoperative glycemic control [5–18]. This
increased postoperative complication rate is
also associated with increased costs [22]. How-
ever, little data are currently available on whe-
ther various preoperative HbA1c targets are
achievable for those undergoing elective surgery
or whether clinicians adhere to these guidelines
before proceeding with surgery. The data from
the present study show that the orthopedic
department adhered relatively closely to the
target HbA1c of 69 mmol/mol. A previous study
by Giori et al. focused on whether people with
diabetes requiring total joint arthroplasty at a
single center in the USA could achieve a pre-
operative HbA1c goal of 53 mmol/mol [23].
These authors found that 94% of their patients
ultimately did achieve the target HbA1c, but
that 15% had their surgery delayed due to poor
glycemic control, similar to our findings. These
results led them to conclude that a goal
designed to reduce perioperative risk should be
achievable but also that it may not be possible
for some patients with DM to achieve this target
HbA1c of\53 mmol/mol. However, Giori et al.
[23] aimed for much tighter glycemic control
than the UK current guidelines, which
recommend an HbA1c of \ 69 mmol/mol [19].
Furthermore, many individuals requiring joint
arthroplasty are elderly, and such ‘tight’ gly-
cemic control may be inappropriate and indeed
harmful in this patient population [24, 25].
Some authors from the USA have shown that
risks of excess postoperative complications first
occur when the HbA1c rises to[58 mmol/mol
[26], and thus a target of\ 58 mmol/mol may
be inappropriate.
The recommended threshold for preopera-
tive HbA1c differs between studies, ranging
between 53 and 75 mmol/mol [6, 26–30]. When
investigating joint infections following total
knee arthroplasty [31] and hip arthroplasty [29],
Cancienne et al. calculated that a target HbA1c
of 64 or 58 mmol/mol, respectively, could be
used. However, for both studies the authors
suggested that HbA1c had poor sensitivity as an
independent predictor of infection.
There are data to suggest that those people
who are hyperglycemic, but not previously
known to have diabetes preoperatively, have
poorer postoperative outcomes than those
known to have diabetes [32–34]. These data
suggest that for those who are at risk of devel-
oping hyperglycemia, pre-operative HbA1c test-
ing may be beneficial [35]. Those people who
may benefit from preoperative testing of HbA1c
are listed in Table 5.
Table 5 People without diabetes who may beneﬁt from
having their pre-operative glycated hemoglobin concen-
tration measured
Aged[ 40 years old ([ 30 years in people of South
Asian origin)
Family history of diabetes
Personal history of gestational diabetes
Personal history of hypertension
Personal history of dyslipidemia
Personal history of prediabetes
Body mass index[ 25 kg m2 (23 kg m2 in those of
South Asian origin)
Those on long-term glucocorticoid treatment
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CONCLUSIONS
In summary, our data show that the majority
(77%) of patients in our convenience sample of
1000 consecutive patients undergoing elective
vascular and orthopedic surgery were able to
achieve a target HbA1c of\ 69 mmol/mol. The
current preoperative guidance is therefore
achievable in a real-life setting. However, as is
stated in the national guidance, this target
should only be used where it is safe to do so and
that a degree of clinical discretion is necessary.
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